Clinic results and changes in humoral immunity of patients with lymphoma in treatment with rituximab
XU Jing-shu
LI Song
CHEN Yangyang
XU Ben
XIANG Hang
Abstract：Objective To observe the effect of rituximab in the treatment of patients with non-Hodgkin's lymphoma and its effect on the level of humoral immunity.Methods Seventy-eight cases of patients with B cell lymphoma were select-ed, which were treated in hospital from February 2012 to February 2016, and were divided into the study group (39 cases) and control group (39 cases).The patients of control group were treated with CHOP regimen of cyclophosphamide 750 mg/m2+vincristine 1.4 mg/m2 +epirubicin 60 mg/m2 , intravenous infusion 3 times /d, and oral prednisone tablets 100 mg/d. On the basis of the control group, the patients of observation group were treated with rituximab injection (375 mg/m2 ,intrave-nous infusion) .A course of two groups were 21 days, and they were all treated with six courses.Compare the clinic results, adverse events;follow up survival and after chemotherapy, changes of the levels of serum immunoglobulins, complement of two groups.Results The patients of the study group got a total efficiency of 64.1%, which was significantly better than the 41.0%of the control group (χ2 =4.165, P =0.041);In terms of IgG, IgM, IgA, there was no significantly difference be-tween the two groups ( t =0.167, t =0.395, t =0.384, P =0.434, P =0.347, P =0.351);The levels of C3, C4 of the study group were significantly less than those of the control group ( t =4.929, t =5.295, P =0.000, P =0.000);There were leukopenia, nausea, vomiting, liver damage, hair loss, bone marrow suppression, anemia, thrombocytopenia and other symptoms occurred in patients of all two groups during treatment, and there was no significantly difference between the two groups ( P >0.05); All patients were followed up 1 to 36 months, with a median follow up time of 19.7 months after chemotherapy;The patients of the study group got a 3 year survival of 39.4%, and the control group got a 3 year survival of 36.2%, there was no significantly difference between the two groups (χ2 =0.218, P =0.642).Conclusion With treating patients with lymphoma, rituximab combined with CHOP can obtain significant clinical efficacy, and it is safety and have a certain effect on serum immunoglobulin and complement.
Keywords：RituximabLymphomaEfficacyImmunoglobulinsComplement
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1048-1051 )